Restem, LLC. Report issue

For profit Phase 2
Founded: Corona CA United States (2020)

Organization Overview

First Clinical Trial
2020
NCT04494386
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Restem, LLC.

Active Ingredients

Drugs in Phase 2 Trials (1)

umbilical cord mesenchymal stem cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Infections (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1